Objective. The objective of this investigation was to determine the effects of testosterone administration on pain catastrophizing and sleep quality in adult men with opioid-induced androgen deficiency.
Design. Sixty-two men aged 18-64 years using opioid analgesics for chronic non-cancer pain with total testosterone levels < 350 ng/dl were randomized to 14 weeks of transdermal testosterone gel or placebo gel daily. Total testosterone levels were measured by liquid chromatography mass spectrometry and free testosterone was calculated using the law of mass action equation. Outcomes were assessed by administering validated instruments such as Pain Catastrophizing Scale (PCS) and Insomnia Severity Index (ISI) at baseline and 14 weeks.
Results. Baseline characteristics were similar between the two groups. Mean (SD) total testosterone concentrations increased from 223 6 86 to 775 6 555 ng/dl in the testosterone group, but did not meaningfully change in placebo group. Mean changes in PCS and ISI scores during intervention did not differ significantly between groups and were not related to changes in on-treatment serum testosterone concentrations.
Introduction
Opioids are potent analgesics that are widely prescribed for the management of acute and chronic pain and their use has rapidly grown in recent years [1, 2] . It has been known for decades that opiates potently suppress the hypothalamic-pituitary-gonadal axis [3] . Indeed, studies evaluating the prevalence of hypogonadism in this patient population have shown that between 70-100% of men on chronic opioids are hypogonadal with some patients experiencing decline in serum testosterone levels in the castrate range [4] . As a result, these men experience decreased libido, erectile dysfunction, decreased muscle mass and osteoporosis [4] [5] [6] . In addition to the above-mentioned symptoms, androgen deficiency has also been associated with increased pain sensitivity in men [7] , while administration of testosterone has been shown to improve pain tolerance in castrated male rodents [8] . We recently demonstrated that testosterone replacement in men with chronic pain and opioidinduced androgen deficiency improves pain perception (i.e., reduces indices of central nervous system sensitization) and pain tolerance [9] suggesting the role of testosterone as an adjunct in enhancing the potency of opioids in these patients.
Patients with chronic pain experience an array of negative cognitive and emotional processes which influence their perception of pain; otherwise known as pain catastrophizing. Pain catastrophizing is defined as a negative cognitive-affective response to anticipated or actual pain [10] . Catastrophizing is considered a significant risk factor for poor pain-related outcomes including increased pain severity, enhanced pain sensitivity and physical disability [11] . Catastrophizing is measured by the validated Pain Catastrophizing Scale (PCS) which ask respondents to report the degree to which they tend to magnify the threat value of pain, feel helpless when in pain and their tendency to ruminate (inability to suppress pain-related thoughts) about pain [10, 12] . In addition to catastrophizing, sleep disturbance is one of the most common problems experienced by patients with chronic pain. Insomnia contributes to a maladaptive response to pain, which results in increased pain sensitivity and reduced efficacy of analgesic medications [13] . The Insomnia Severity Index (ISI) is a validated instrument that is widely used to assess perceived insomnia severity in sleep disorder clinics and has been used to assess sleep quality in patients with chronic pain [14] . Although we recently showed that testosterone replacement improves pain perception and tolerance in men with opioid-induced androgen deficiency, the effects of testosterone on pain catastrophizing and sleep disturbance, two robust risk factors for adverse chronic pain-related outcomes, has not been previously studied.
Given the evidence that greater degree of catastrophizing and sleep disturbance are associated with poor pain prognosis and can interfere with efficacy of pharmacologic treatment for chronic pain [10, 11, 13] , it is important to determine whether testosterone replacement in men with opioid-induced androgen deficiency can improve these outcomes. Accordingly, we evaluated the effects of testosterone administration on pain catastrophizing severity using the PCS and insomnia severity using the ISI to determine if normalizing testosterone levels can have beneficial effects on these outcomes in this patient population.
Methods

Study Design
The eligibility criteria and design of the testosterone and pain (TAP) trial have been published [9] and are briefly described here. This single-center, parallel group, placebo-controlled, double-blind randomized trial was approved by the Institutional Review Board of Boston University Medical Center. All participants provided written informed consent.
Eligibility
The participants were community-dwelling men, 18-64 years of age, who were using opioid analgesics for chronic non-cancer pain and had a morning total testosterone less than 350 ng/dL as measured by liquid chromatography-tandem mass spectrometry (LC-MS/ MS). Participants were required to have been taking at least 20 mg of hydrocodone (or morphine equivalent dose of another opioid) daily for at least 4 weeks. We excluded men with previous history of organic hypogonadism, active psychiatric illness such as schizophrenia, psychosis, manic-depressive disorder or major depression, any malignancy, severe lower urinary tract symptoms, prostate specific antigen > 4 ng/mL, diabetes, congestive heart failure, recent myocardial infarction, unstable angina, uncontrolled congestive heart failure, uncontrolled hypertension, peripheral vascular disease, and chronic obstructive pulmonary disease. Men using testosterone, growth hormone, or other anabolic therapy, and drugs that affect gonadal function were also excluded.
Randomization and Study Intervention
Eligible participants were randomized to either a placebo or testosterone gel using a concealed computergenerated randomization table. The participants and outcome assessors were blinded to the randomized assignment.
The participants applied daily transdermal gel containing either placebo or 5 g of transdermal testosterone gel (Androgel 1%; Abbvie Pharmaceuticals) once daily for 14 weeks. Our aim was to raise serum testosterone levels into the mid-normal range for healthy young men (500-1000 ng/dl). Two weeks after randomization, the dose of testosterone gel was adjusted by an unblinded study physician if the serum total testosterone level was < 500 ng/dl, in which case the dose was increased to 7.5 g daily. For any participant in the testosterone group requiring a dose increase, a placebo participant was chosen at random by the unblinded physician and was assigned a (simulated) dose increase, thus maintaining blinding to treatment assignment.
Hormone Measurements
Serum total testosterone levels were measured by LC-MS/MS with sensitivity of 2 ng/dl [15] . The crossreactivity of DHEA, DHEAS, DHT, androstenedione and estradiol in the testosterone assay was negligible at ten times the circulating concentrations of these hormones. The interassay coefficient of variation was 15.8%, at 12.0 ng/dL, 10.6%, at 23.5 ng/dL, 7.9%, at 48.6 ng/dL, 7.7% at 241 ng/dL, 4.4% at 532 ng/dL, and 3.3% at 1016 ng/dL respectively. As part of the Centers for Disease Control's (CDC) Testosterone Assay Harmonization Initiative, quality control samples provided by the CDC were run every three months; the bias in quality control samples in the 3.47-34.7 nmol/L (100-1000 ng/dL) range was < 6.2%. Free testosterone was calculated using a published law-of-mass-action equation [16] . Sex hormone binding globulin levels were measured using an immunofluorometric assay with sensitivity 2.5 nmol/L [16] .
Pain Catastrophizing Scale
Self-assessment of pain catastrophizing was measured using the PCS questionnaire before and after 14-weeks of intervention [12] . This questionnaire consists of 13 items asking individuals to reflect on past painful experiences and rate the degree (on an increasing scale ranging from 0 to 4) to which they experience negative painrelated thoughts. These items address three domains of pain catastrophizing: rumination, magnification and helplessness; relevant items for each domain are summed to generate three subscales, which in turn are added together to generate the overall PCS score with range 0-52 [12] .
Insomnia Severity Index
Self-assessment of insomnia was measured using the ISI before and after 14 weeks of intervention [14] . The ISI is comprised of seven items assessing a participant's perception of insomnia that specifically address the symptoms and consequences of insomnia, as well as the degree of distress caused by sleep quality [14] . Each item is rated on a scale of increasing severity ranging from 0 to 4, and scores from the questions are summed to assign a total score ranging from 0 to 28.
Statistical Considerations
Exploratory analyses were employed to assess distributional properties of outcomes variables in each of the randomized groups. Graphical depictions were generated to assess empirical evidence in favor of differences and associations. Mean change in outcomes for each group were estimated using mean sample differences and associated 95% confidence intervals. The statistical significance of differences between arms in change in outcomes was determined using Student's T-tests allowing for unequal variances. Association between change in testosterone levels and change in outcomes was assessed using scatterplots, with smoothing by Generalized Additive Models (GAM), which allow for curvilinearity in trends. Multiple linear regression analysis was used to assess the magnitude and statistical significance of these relationships adjusting for age, body mass index (BMI) and baseline outcomes measurements. The design described above provides 80% power to detect a standardized treatment effect of 0.74. Assuming standard deviations of 10 and 5 points on PCS composite and ISI, respectively, these effects translate to 7.4 point and 3.0 point differences.
Results
Baseline Characteristics
Of the 84 men randomized in the original study, 65 men completed the study (36 in the testosterone arm and 29 in the placebo arm). Of the completers, 62 men (33 in the testosterone arm and 29 in the placebo arm) had pre and post-intervention data on PCS and ISI outcomes and constituted our analytical sample. The baseline characteristics of the study population are summarized in Table 1 . Mean (standard deviation; SD) age at baseline was 48 (8) years. The mean (SD) total and free testosterone concentrations were 223 (86) ng/ dl and 237 (97) in the testosterone and placebo group, respectively. Mean (SD) free testosterone levels were 44 (23) pg/ml and 44 (19) pg/ml in the testosterone and placebo groups, respectively. The mean (SD) morphine equivalent opiod dose at baseline was 116 mg in the testosterone arm and 76 mg in the placebo arm. Baseline age, BMI, scores on PCS were similar in the two arms. The mean ISI scores, which were consistent with subclinical sleep disturbance, were also similar between the two groups.
Hormone Levels
Mean (SD) serum total testosterone concentrations increased from 223 (86) to 775 (555) ng/dl in the testosterone group, but did not change significantly in the placebo group. Similarly, mean on-treatment free testosterone concentrations increased from 44 (23) to 184(154) pg/ml in the testosterone arm. Of the 33 men randomized to the testosterone arm, 23 required a testosterone dose increase from 5 g to 7.5 g daily to achieve a predefined target range of serum testosterone between 500 and 1000 ng/dl.
Effect of Testosterone on Pain Catastrophizing
Changes in pain catastrophizing scores are depicted by treatment arm in Figure 1 . Both groups had moderate improvements in their scores on all of the domains of pain-catastrophizing. However, when compared with placebo, the testosterone arm evidenced no significant effect on either the total score or subscale scores on the PCS questionnaire from baseline to the end of treatment. The mean (95% Confidence Interval) difference between the arms on PCS composite was 1.0 (À3.7, 5.6).
Differences were similarly inconsequential for each of the PCS subscores. Relationships between change in serum testosterone concentrations and PCS restricted to subjects randomized to testosterone, as estimated in linear regression analyses, are depicted in Table 2 . Changes in PCS were not significantly related to changes in serum testosterone concentrations among these men.
Effect of Testosterone on Insomnia Severity Index
Changes in ISI questionnaire are depicted by treatment arm in Figure 1 . Although there was a greater improvement in the insomnia severity index in the testosterone arm compared with placebo, this difference was not significant statistically. The mean (95% Confidence Interval) difference between the arms on ISI was À0.62 (À2.6, 1.4). Among individuals randomized to testosterone. These changes were not significantly related to increases in testosterone concentrations (Table 2) .
Discussion
Substantial evidence from animal studies supports the notion that gonadal hormones influence pain and analgesia. Castrated male rodents undergoing hormone replacement with exogenous testosterone showed greater tolerance to noxious stimuli compared to gonadectomized rodents not given testosterone [8, 17] , suggesting that testosterone possesses analgesic properties. We recently reported that testosterone replacement in men using opiates for chronic pain who have opioid-induced androgen deficiency improved pain perception and pain tolerance [9] . However, in that report, we had not evaluated whether the observed improvements in pain outcomes with testosterone replacement were mediated via improvements in phenotypic biopsychosocial variables that shape long-term pain-related outcomes, such as pain catastrophizing. Catastrophizing is a critically important psychosocial factor that significantly influences the long-term course and nature of pain. Catastrophizing involves a specific set of negative painrelated cognitive and emotional processes that can potentially increase the level of pain perceived by patients by inhibiting the effectiveness of opioid-mediated analgesic pathways in the central nervous system [11] . Furthermore, patients who have lower levels of catastrophizing are more likely to achieve benefit in terms of reduction in pain and disability with various pain treatment modalities than those with higher levels [18] [19] [20] . Thus, high levels of catastrophizing may lead to a viscious cycle resulting in perpetuation of chronic pain despite being on opioids resulting in long-term requirements of even higher doses of opiates.
We therefore evaluated whether testosterone administration could reduce pain catastrophizing in men with opioid-induced androgen deficiency. In this first randomized-controlled trial of men with opioid-induced androgen deficiency, testosterone replacement for 14 weeks did not result in reductions in pain catastrophizing despite improvements in pain perception and tolerance [9] .
With the substantial rise in opioid prescriptions for the treatment of chronic pain, there has been a growing number of observational studies associating high levels of catastrophizing with increased risk for prescription opioid misuse [10] . Thus, therapies targeting reductions in pain catastrophizing may result in improved long-term pain-related outcomes. Our recent observation of testosterone improving pain perception and pain tolerance in men with opioid-induced androgen deficiency [9] led us to explore whether these improvements are due to improvement in catastrophizing. Interestingly, we did not observe significant improvements within the testosterone arm in any of the three dimensions of pain catastrophizing (rumination, magnification and helplessness) in this study. These findings suggest that the observed beneficial effects of testosterone replacement in improving pain perception and tolerance in this population are mediated by different mechanisms (e.g., direct effect on nociceptors), which require further investigation.
Patients with chronic pain, particularly those on opioids, also experience higher rates of sleep impairment and poor sleep quality than the general population [21, 22] . Evidence from several animal and human studies suggests that disordered sleep can negatively affect pain sensitivity and analgesic response to pain treatment [23, 24] . Furthermore, low testosterone levels have been also associated with poor sleep efficiency, increased nocturnal waking and reduced slow wave sleep [25] . In animal experiments, testosterone replacement in castrated male rodents exhibit an increase in non-REM sleep [26] . Given that men on opioids develop sleep disorders [27] , which could be further exacerbated as a result of opioid-induced androgen deficiency, we hypothesized that our finding of improvement in pain perception with testosterone replacement might have been mediated by an improvement in sleep quality. However; in this trial, testosterone replacement did not improve self-reported sleep quality as measured by validated ISI questionnaire. Our findings could be explained by the fact that the organizational and activational effects of sex steroids only partly influence sleep rhythms [28] . Indeed, in another study, testosterone replacement was not shown to improve sleep quality in men with secondary hypogonadism [28] .
Our study has notable strengths and some limitations. This trial brings novelty to the field of pain medicine and andrology as the effects of testosterone administration on pain catastrophizing and sleep disturbance in men with opioid-induced androgen deficiency have not been previously studied. The trial had many features of exemplary trial design: concealed randomization, placebo-control, blinding, parallel group design, and oversight by an independent DSMB. Total testosterone was measured using liquid chromatographytandem mass spectrometry, widely considered the reference method with the highest sensitivity and specificity. Testosterone dose was adjusted in a blinded manner to maintain testosterone levels in the target range. The baseline mean total and free testosterone levels in our study were well below the lower limits of normal established in community-based samples and consistent with previous data in men with opioidinduced androgen deficiency [15, 29] . However, it is possible that statistically significant changes in pain catastrophizing and sleep quality may be seen in men with testosterone levels lower than men evaluated in our trial. It is also possible that our results were limited by large placebo effects as both treatment arms demonstrated moderate improvements in our PCS and ISI outcomes. Although the 14-week intervention duration is similar to many other testosterone replacement trials, it is conceivable that this intervention period might not have been long enough to demonstrate a significant change in pain catastrophizing or sleep parameters, as these biopsychosocial processes that shape pain responses might require longer intervention. Thus, long-term studies are needed to further evaluate if pain catastrophizing and sleep quality are improved with testosterone replacement.
In conclusion, testosterone administration for 14 weeks in men with opioid-induced androgen deficiency was not associated with improvements in pain catastrophizing or sleep quality. These findings shed additional light on the potential mechanisms by which testosterone may produce beneficial analgesic effects. Collectively, it appears that the improvement in pain parameters as a result of testosterone replacement in patients with opioid-induced androgen deficiency is mediated by mechanisms other than improvements in pain catastrophizing and sleep quality. Our previous analyses had also suggested that these beneficial effects were not achieved via reductions in inflammatory markers [9] . We hope that these findings will help to stimulate additional research on the specific pathways by which testosterone replacement effects improvements in pain-related outcomes. b coefficients represent change in PCS/ISI parameters as a function of every 100 ng/dl (3.5 nmol/l) change in total and every 10 pg/ml (35 pmol/l) change in free testosterone levels, respectively.
